Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year

Affiliations

• ¹ Brigham and Women's Hospital, Boston, Massachusetts, USA.
• ² Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
• ³ Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
• ⁴ Lahey Dermatology, Burlington, Massachusetts, USA.
• ⁵ Harvard Medical School, Boston, Massachusetts, USA.
• ⁶ Eli Lilly and Company, Indianapolis, Indiana, USA.
• ⁷ Tiger Med Group, Wayne, New Jersey, USA.
• ⁸ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.